Rhenman & Partners Asset Management AB Buys Gilead Sciences Inc, Medtronic PLC, Pfizer Inc, Sells Shire PLC, Celgene Corp, Alexion Pharmaceuticals Inc

• New Purchases: GILD, MDT, PFE, ANTM, ILMN, AERI, BDX, MYL, STAA, BUD,
• Added Positions: HZNP, CNC, GKOS, EXEL, TEVA, HUM, NVRO, TMO, ARIA, BMY,
• Reduced Positions: CELG, ALXN, BMRN, MRK, UNH, BIIB, ALKS, INCY, WBA, LLY,
• Sold Out: SHPG, MCK, CEMP, COO, RAD, JNJ, VRX,

For the details of Rhenman & Partners Asset Management AB's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Rhenman+%26+Partners+Asset+Management+AB

1. Gilead Sciences Inc (GILD) - 259,894 shares, 3.57% of the total portfolio. New Position
2. Bristol-Myers Squibb Company (BMY) - 281,000 shares, 3.15% of the total portfolio. Shares added by 18.57%
3. Allergan PLC (AGN) - 76,000 shares, 3.06% of the total portfolio. Shares reduced by 4.4%
4. Eli Lilly and Co (LLY) - 215,000 shares, 3.03% of the total portfolio. Shares reduced by 15.69%
5. Medtronic PLC (MDT) - 215,240 shares, 2.94% of the total portfolio. New Position

Rhenman & Partners Asset Management AB initiated holdings in Gilead Sciences Inc. The purchase prices were between $71.61 and $78.47, with an estimated average price of $74.33. The stock is now traded at around $73.51. The impact to the portfolio due to this purchase was 3.57%. The holdings were 259,894 shares as of 2016-12-31.

Rhenman & Partners Asset Management AB initiated holdings in Medtronic PLC. The purchase prices were between $71.23 and $86.39, with an estimated average price of $78.56. The stock is now traded at around $74.71. The impact to the portfolio due to this purchase was 2.94%. The holdings were 215,240 shares as of 2016-12-31.

Rhenman & Partners Asset Management AB initiated holdings in Pfizer Inc. The purchase prices were between $29.89 and $33.9, with an estimated average price of $32.18. The stock is now traded at around $32.55. The impact to the portfolio due to this purchase was 2.08%. The holdings were 333,300 shares as of 2016-12-31.

Rhenman & Partners Asset Management AB initiated holdings in Anthem Inc. The purchase prices were between $117.42 and $147.66, with an estimated average price of $133.9. The stock is now traded at around $147.94. The impact to the portfolio due to this purchase was 1.61%. The holdings were 58,257 shares as of 2016-12-31.

Rhenman & Partners Asset Management AB initiated holdings in Illumina Inc. The purchase prices were between $122.02 and $186.17, with an estimated average price of $138.55. The stock is now traded at around $164.51. The impact to the portfolio due to this purchase was 0.37%. The holdings were 15,000 shares as of 2016-12-31.

Rhenman & Partners Asset Management AB initiated holdings in Aerie Pharmaceuticals Inc. The purchase prices were between $32.8 and $42.2, with an estimated average price of $37.82. The stock is now traded at around $41.55. The impact to the portfolio due to this purchase was 0.25%. The holdings were 35,000 shares as of 2016-12-31.

Rhenman & Partners Asset Management AB added to the holdings in Horizon Pharma PLC by 91.78%. The purchase prices were between $14.55 and $21.7, with an estimated average price of $18.13. The stock is now traded at around $17.54. The impact to the portfolio due to this purchase was 1.04%. The holdings were 700,000 shares as of 2016-12-31.

Rhenman & Partners Asset Management AB added to the holdings in Centene Corp by 87.50%. The purchase prices were between $50.68 and $66.8, with an estimated average price of $59.01. The stock is now traded at around $62.91. The impact to the portfolio due to this purchase was 0.76%. The holdings were 150,000 shares as of 2016-12-31.

Rhenman & Partners Asset Management AB added to the holdings in Glaukos Corp by 2170.59%. The purchase prices were between $30.61 and $38.73, with an estimated average price of $34.23. The stock is now traded at around $40.00. The impact to the portfolio due to this purchase was 0.73%. The holdings were 115,800 shares as of 2016-12-31.

Rhenman & Partners Asset Management AB added to the holdings in Exelixis Inc by 38.33%. The purchase prices were between $10.2 and $18.25, with an estimated average price of $14.43. The stock is now traded at around $19.04. The impact to the portfolio due to this purchase was 0.66%. The holdings were 830,000 shares as of 2016-12-31.

Rhenman & Partners Asset Management AB added to the holdings in Teva Pharmaceutical Industries Ltd by 33.33%. The purchase prices were between $35.03 and $45.68, with an estimated average price of $39.93. The stock is now traded at around $34.00. The impact to the portfolio due to this purchase was 0.63%. The holdings were 360,000 shares as of 2016-12-31.

Rhenman & Partners Asset Management AB added to the holdings in Humana Inc by 60.00%. The purchase prices were between $165.31 and $216.76, with an estimated average price of $190.72. The stock is now traded at around $205.84. The impact to the portfolio due to this purchase was 0.59%. The holdings were 40,000 shares as of 2016-12-31.

Rhenman & Partners Asset Management AB sold out the holdings in Shire PLC. The sale prices were between $163.77 and $197.7, with an estimated average price of $177.25.

Rhenman & Partners Asset Management AB sold out the holdings in McKesson Corp. The sale prices were between $124.11 and $165.82, with an estimated average price of $147.1.

Rhenman & Partners Asset Management AB sold out the holdings in Cempra Inc. The sale prices were between $2.6 and $23.97, with an estimated average price of $12.13.

Rhenman & Partners Asset Management AB sold out the holdings in The Cooper Companies Inc. The sale prices were between $159.5 and $182.9, with an estimated average price of $174.7.

Rhenman & Partners Asset Management AB sold out the holdings in Rite Aid Corp. The sale prices were between $6.43 and $8.61, with an estimated average price of $7.55.

Rhenman & Partners Asset Management AB sold out the holdings in Johnson & Johnson. The sale prices were between $110.99 and $120.31, with an estimated average price of $115.51.